Capivasertib-Fulvestrant Therapy Increases PFS in HR-Positive Breast Cancer
Elana Gotkine
MONDAY, June 5, 2023 (HealthDay News) -- For patients with hormone receptor-positive advanced breast cancer with disease…
Browsing Tag
PFS
Nivolumab-AVD Boosts PFS in Untreated Hodgkin Lymphoma
CHICAGO -- Adding the immune checkpoint inhibitor nivolumab (Opdivo), rather than brentuximab vedotin (Adcetris),…
Pricey Drug Combo Boosts PFS in First-Line Advanced Ovarian Cancer
CHICAGO -- A three-drug combination significantly improved progression-free survival (PFS) in newly diagnosed…
Anti-EGFR Rechallenge Boosts PFS in Third-Line Metastatic Colorectal Cancer
Rechallenge with an EGFR inhibitor in addition to standard therapy led to…
Allo-Transplant Tied to Better PFS in Advanced Cutaneous T-Cell Lymphomas
Allogeneic hematopoietic stem cell transplantation (HSCT) was associated with…
Adding Talazoparib to Enzalutamide Boosts PFS in Metastatic Prostate Cancer
SAN FRANCISCO -- Treatment with the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) significantly improved…
Is PFS Benefit Enough to Support Upfront Transplant in Multiple Myeloma?
DETERMINATION is one of many recent randomized trials in newly diagnosed transplant-eligible multiple…
G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression…
RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided an initial update on PRESERVE 3,…
Adding AKT Inhibitor Doubles PFS in Advanced, HR-Positive Breast Cancer
SAN ANTONIO -- Addition of an investigational AKT inhibitor to standard fulvestrant (Faslodex) doubled median progression-free…
Oral SERD Tops Fulvestrant for PFS in ER-Positive Breast Cancer
The next-generation oral selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival (PFS)…